These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases. Liu C; Lin J; Wrobleski ST; Lin S; Hynes J; Wu H; Dyckman AJ; Li T; Wityak J; Gillooly KM; Pitt S; Shen DR; Zhang RF; McIntyre KW; Salter-Cid L; Shuster DJ; Zhang H; Marathe PH; Doweyko AM; Sack JS; Kiefer SE; Kish KF; Newitt JA; McKinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K J Med Chem; 2010 Sep; 53(18):6629-39. PubMed ID: 20804198 [TBL] [Abstract][Full Text] [Related]
7. Synthesis of carbon-11-labeled 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine derivatives as new potential PET tracers for imaging of p38α mitogen-activated protein kinase. Wang M; Gao M; Zheng QH Bioorg Med Chem Lett; 2014 Aug; 24(16):3700-5. PubMed ID: 25065491 [TBL] [Abstract][Full Text] [Related]
9. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold. Herberich B; Cao GQ; Chakrabarti PP; Falsey JR; Pettus L; Rzasa RM; Reed AB; Reichelt A; Sham K; Thaman M; Wurz RP; Xu S; Zhang D; Hsieh F; Lee MR; Syed R; Li V; Grosfeld D; Plant MH; Henkle B; Sherman L; Middleton S; Wong LM; Tasker AS J Med Chem; 2008 Oct; 51(20):6271-9. PubMed ID: 18817365 [TBL] [Abstract][Full Text] [Related]
10. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors. Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813 [TBL] [Abstract][Full Text] [Related]
11. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. de Dios A; Shih C; López de Uralde B; Sánchez C; del Prado M; Martín Cabrejas LM; Pleite S; Blanco-Urgoiti J; Lorite MJ; Nevill CR; Bonjouklian R; York J; Vieth M; Wang Y; Magnus N; Campbell RM; Anderson BD; McCann DJ; Giera DD; Lee PA; Schultz RM; Li LC; Johnson LM; Wolos JA J Med Chem; 2005 Apr; 48(7):2270-3. PubMed ID: 15801819 [TBL] [Abstract][Full Text] [Related]
12. 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase. Pettus LH; Xu S; Cao GQ; Chakrabarti PP; Rzasa RM; Sham K; Wurz RP; Zhang D; Middleton S; Henkle B; Plant MH; Saris CJ; Sherman L; Wong LM; Powers DA; Tudor Y; Yu V; Lee MR; Syed R; Hsieh F; Tasker AS J Med Chem; 2008 Oct; 51(20):6280-92. PubMed ID: 18817364 [TBL] [Abstract][Full Text] [Related]
13. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography. Gill A; Cleasby A; Jhoti H Chembiochem; 2005 Mar; 6(3):506-12. PubMed ID: 15696598 [TBL] [Abstract][Full Text] [Related]
14. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor. Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Schieven GL; Gillooly KM; Shuster DJ; Taylor TL; Yang X; McIntyre KW; McKinnon M; Zhang H; Marathe PH; Doweyko AM; Kish K; Kiefer SE; Sack JS; Newitt JA; Barrish JC; Dodd J; Leftheris K Bioorg Med Chem Lett; 2008 Mar; 18(6):1762-7. PubMed ID: 18313298 [TBL] [Abstract][Full Text] [Related]
16. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase. Pettus LH; Wurz RP; Xu S; Herberich B; Henkle B; Liu Q; McBride HJ; Mu S; Plant MH; Saris CJ; Sherman L; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS J Med Chem; 2010 Apr; 53(7):2973-85. PubMed ID: 20218619 [TBL] [Abstract][Full Text] [Related]
17. Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase. Jerome KD; Hepperle ME; Walker JK; Xing L; Devraj RV; Benson AG; Baldus JE; Selness SR Bioorg Med Chem Lett; 2010 May; 20(10):3146-9. PubMed ID: 20395140 [TBL] [Abstract][Full Text] [Related]
18. 5-amino-pyrazoles as potent and selective p38α inhibitors. Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336 [TBL] [Abstract][Full Text] [Related]
19. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. Aston NM; Bamborough P; Buckton JB; Edwards CD; Holmes DS; Jones KL; Patel VK; Smee PA; Somers DO; Vitulli G; Walker AL J Med Chem; 2009 Oct; 52(20):6257-69. PubMed ID: 19772287 [TBL] [Abstract][Full Text] [Related]
20. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase. Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]